Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4–ALK Fusion Gene

Overview of attention for article published in Annals of Surgical Oncology, November 2009

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (87th percentile)
Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

policy: 1 policy source

patent: 7 patents

Citations

dimensions_citation: 303 Dimensions

Readers on

mendeley: 118 Mendeley

Summary Policy documents Patents Dimensions citations

So far, Altmetric has seen 2 policy documents that reference this research output.

Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer : Appraisal consultation committee papers

Cited by National Institute for Health and Care Excellence on 24 Jan 2020

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Ceritinib for untreated ALK-positive non-small-cell lung cancer: Committee papers

Cited by National Institute for Health and Care Excellence on 24 Nov 2017

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.